[18F]FET PET引导的胶质母细胞瘤假性进展管理(FET POPPING):一项诊断性随机临床试验的研究方案
FET POPPING是一项多中心诊断性随机临床试验,计划于2024年8月至2027年12月纳入144例IDH野生型胶质母细胞瘤成人患者,这些患者在标准替莫唑胺放化疗联合阶段后至少≥3个月出现MRI新发或增大的对比增强,难以鉴别肿瘤生长与假性进展。患者按1:1随机分为两组,试验组额外接受[18F]FET PET扫描并联合索引MRI指导临床管理,对照组仅基于索引MRI。主要终点为接受不必要干预的患者百分比和12周后健康相关生活质量。
要点
- 针对放化疗后MRI对比增强难以鉴别肿瘤生长与假性进展的IDH野生型胶质母细胞瘤成人患者。
- 试验组额外接受[18F]FET PET扫描,临床管理基于索引MRI与[18F]FET PET联合。
- 主要终点为不必要干预的患者百分比和12周后健康相关生活质量。
核心结论
- 作者假设,与仅基于MRI的管理相比,额外[18F]FET PET扫描引导的临床管理可减少不必要干预、改善12周后健康相关生活质量并降低净医疗费用。
研究设计与样本
- 多中心诊断性随机临床试验,计划于2024年8月至2027年12月进行。
- 计划纳入144例成人IDH野生型胶质母细胞瘤患者,这些患者在标准替莫唑胺放化疗联合阶段后至少≥3个月出现MRI新发或增大的对比增强,难以鉴别肿瘤生长与假性进展。
- 患者按1:1随机分为两组:试验组额外接受[18F]FET PET扫描,临床管理基于索引MRI与[18F]FET PET联合;对照组临床管理仅基于索引MRI。
- 具体临床管理由当地多学科委员会根据可用影像自行决定。
主要发现
- 主要研究终点为:(a)接受不必要干预的患者百分比;(b)12周后健康相关生活质量。
- 次要终点包括诊断时间、总生存期和成本效果。
关键数值与推荐
- 假性进展在本试验中作为涵盖性术语,包括放射性坏死和(放)化疗后其他治疗相关改变。
- 纳入标准要求患者在标准替莫唑胺放化疗联合阶段后至少≥3个月出现MRI新发或增大的对比增强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During follow-up of glioblastoma patients after chemoradiation, expert teams often observe abnormalities on MRI with difficulty in distinguishing between tumor growth and pseudoprogression. Although advanced MRI techniques such as perfusion weighted imaging provide additional information, diagnostic uncertainty often remains, leading to incorrect or delayed diagnosis, and inappropriate treatment, such as unnecessary surgery. [18F]Fluoro-ethyl-tyrosine positron emission tomography (FET PET) has good discriminating power for this setting. Still, this diagnostic tool is not used frequently in The Netherlands due to costs, logistics and uncertainty about clinical benefit. In the FET POPPING study, we aim to determine the added value of [18F]FET PET for clinical management of glioblastoma patients. METHODS: A multicenter diagnostic randomized clinical trial will be performed, from August 2024 until December 2027. Adult patients (n=144) with isocitrate dehydrogenase (IDH)-wildtype glioblastoma will be included, who, at least ≥3 months after the concomitant phase of standard temozolomide-based chemoradiation, have new or increased contrast enhancement on MRI, causing doubt between tumor growth or pseudoprogression. In this trial, pseudoprogression will be used as an encompassing term that includes radionecrosis and other treatment-related changes after (chemo-)radiotherapy. Included patients will be randomized 1:1 in two arms. The investigational arm receives an additional [18F]FET PET scan, and clinical management is based on the index MRI and [18F]FET PET together. Clinical management of the control arm is based on the index MRI alone. Exact clinical management, as based on the available imaging, is chosen at the discretion of the local multidisciplinary board. The primary study endpoints are (a) the percentage of patients undergoing unnecessary interventions and (b) health-related quality of life after 12 weeks. Secondary endpoints include time-to-diagnosis, overall survival, and cost-effectiveness. DISCUSSION: We hypothesize that the clinical management guided by an additional [18F]FET PET scan leads to fewer unnecessary interventions, better health-related quality of life after 12 weeks and among others reduced net healthcare costs, compared with management based on MRI only. TRIAL REGISTRATION: The trial is registered on ClinicalTrials.gov on the 24th of June 2024, with registration number NCT06480721.
引用
- Ruijters VJ, Snijders TJ, van der Pol JAJ, et al. [18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial. Trials. 2025. PMID: 40528226. doi:10.1186/s13063-025-08921-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。